PIRAMAL PHARMA LIMITED

Ananta Building, Piramal Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400 070

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2026

(Rs. in Crores)

Particulars	Three months ended June 30, 2026	Three months ended March 31, 2026	Three months ended June 30, 2025	For the year ended March 31, 2026
	(Unaudited)	(Refer note 5)	(Unaudited)	(Audited)
Revenue from operations	1,124.95	1,489.06	969.88	4,782.01
Other income (Net)	114.63	183.69	180.92	662.73
Total Income	**1,239.58**	**1,672.75**	**1,150.80**	**5,444.74**
Expenses				
Cost of materials consumed	649.70	234.93	409.76	1,342.70
Purchases of stock-in-trade	234.64	194.03	192.27	866.18
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(390.29)	225.25	(175.87)	(138.98)
Employee benefits expense	216.34	166.55	201.95	744.82
Finance costs	16.36	19.50	23.23	79.95
Depreciation & amortisation expense and impairment charge	65.73	70.12	59.44	255.50
Other expenses (Net)	297.62	364.95	297.44	1,325.29
Total Expenses	**1,090.10**	**1,275.33**	**1,008.22**	**4,475.46**
Profit before exceptional items and tax	**149.48**	**397.42**	**142.58**	**969.28**
Exceptional items (Refer Note 3)	-	(65.57)	-	(92.51)
Profit before tax	**149.48**	**331.85**	**142.58**	**876.77**
Tax Expense				
Current tax-(including prior year taxes)	24.93	43.11	19.63	114.68
Deferred tax (Net)	11.07	27.11	9.81	62.08
Total tax expenses	**36.00**	**70.22**	**29.44**	**176.76**
Net Profit after tax	**113.48**	**261.63**	**113.14**	**700.01**
Other Comprehensive Income / (Loss) (OCI), net of tax expense				
A. Items that will not be reclassified to profit or loss				
Remeasurement of post employment benefit plans	(9.76)	(10.19)	(4.87)	(12.50)
Income tax impact on above	2.46	2.56	1.23	3.15
B. Items that will be subsequently reclassified to profit or loss				
Deferred gains/(loss) on cash flow hedge	3.07	(3.35)	1.24	(35.25)
Income tax impact on above	(0.77)	0.84	(0.31)	8.87
Total Other Comprehensive Income/(Loss), net of tax expense	**(5.00)**	**(10.14)**	**(2.71)**	**(35.73)**
Total Comprehensive Income for the period	**108.48**	**251.49**	**110.43**	**664.28**
Paid-up Equity Share Capital (Face Value of Rs. 10/- each)	1,327.35	1,327.16	1,324.82	1,327.16
Other Equity				6,813.97
Earnings Per Equity Share (EPS) (Face Value of Rs. 10/- each) (restated, not annualised for the quarters)				
a) Basic EPS for the period/year (Rs.)	0.85	1.97	0.85	5.28
b) Diluted EPS for the period/year (Rs.)	0.85	1.96	0.85	5.25

See accompanying notes to the unaudited standalone financial results

Piramal
Pharma Limited

Notes:

1 The unaudited standalone financial results of the Company for the three months ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on July 29, 2026. The Statutory auditors of the Company have carried out a limited review of these results.

2 The unaudited standalone financial results of the Company for the three months ended June 30, 2026 have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3 There were no exceptional items during the quarter ended 30 June 2026. Exceptional items for the quarter and year ended 31 March 2026 aggregating Rs.92.51 crore comprised (i) impairment of an intangible asset under development of Rs.65.57 crore and (ii) incremental employee benefit cost of Rs.26.94 crore arising from the Company's assessment of the impact of the Labour Codes.

4 The Company operates in only one segment and hence segment disclosure is not applicable.

5 The figures for the last quarter of the previous financial year are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of third quarter of the previous financial year which were subjected to limited review by statutory auditors.

For **PIRAMAL PHARMA LIMITED**

PIRAMAL PHARMA LIMITED

July 29, 2026, Mumbai

Nandini Piramal
Chairperson

SURESH SURANA & ASSOCIATES LLP
Chartered Accountants
MUMBAI

Suresh Surana & Associates LLP
Chartered Accountants

Suresh Surana & Associates LLP
308-309, Technopolis Knowledge Park
Mahakali Caves Road, Andheri (E)
Mumbai – 400 093, India
T + 91 (22) 6108 5555
emails@ss-associates.com www.ss-associates.com
LLP Identity No. AAB-7509

Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors of
Piramal Pharma Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Piramal Pharma Limited** ("the Company"), for the quarter ended 30 June 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") as amended, read with relevant Rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information is limited primarily to inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards specified under Section 133 of the Act, as amended read with relevant Rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

SURESH SURANA & ASSOCIATES LLP
Chartered Accountants
MUMBAI

Other Matter

5. We draw attention to the fact that figures for the corresponding quarter ended 30 June 2025, prepared in accordance with Ind AS and included in the Statement, are based on the previously issued unaudited standalone financial results which were reviewed by the predecessor auditor, who had expressed an unmodified conclusion thereon as per their limited review report dated 28 July 2025.

   Our conclusion on the Statement is not modified in respect of this matter.

For Suresh Surana & Associates LLP
Chartered Accountants
Firm Reg. No. 121750W/W100010

SURESH SURANA & ASSOCIATES LLP
Chartered Accountants
MUMBAI

Santosh Maller
Partner
Membership No.: 143824
UDIN: 26143824XHSHFV4878
Place: Mumbai
Date: 29 July 2026